Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 72-77

  Zinner, Stephen H ^a,c   Gilbert, Deborah ^a   Dudley, Michael N ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SULTAMICILLIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; COLONY FORMING UNIT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION;

EID: 0031983331     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.72     Document Type: Article

References (19)

1. Bacquero, F., and the Task Force of the General Direction for Health Planning of the Spanish Ministry of Health. 1996. Antibiotic resistance in Spain: what can be done? Clin. Infect. Dis. 23:819-823.
2. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob. Agents Chemother. 27:343-349.
3. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Two-compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15(Suppl. A):131-137.
4. Bonilla, H. F., L. T. Zarins, S. F. Bradley, and C. A. Kaufmann. 1996. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagn. Microbiol. Infect. Dis. 26:17-21.
5. Centers for Disease Control and Prevention. 1993. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42:597-599.
6. Child, J., F. Boswell, N. Brenwald, J. M. Andrews, and R. Wise. 1995. The in vitro activity of CP-99,219, a new naphthyridone antimicrobial: a comparison with fluoroquinolone agents. J. Antimicrob. Chemother. 35:869-876.
7. Citron, D. M., N. Fiorentino, M. Jiminez, R. Leal, and M. D. Appleman. 1996. Comparative in vitro activity of trovafloxacin (TV) with ten other agents against 275 strains of aerobic and anaerobic organisms isolated from patients with intraabdominal infection, abstr. E80, p. 95. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Cohen, M. A., M. D. Huband, J. W. Gage, and S. L. Yoder. 1996. In vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin, abstr. E85, p. 96. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Cormican, M. G., and R. N. Jones. 1996. In-vitro activity of trovafloxacin (CP-99,219) tested by two methods against 150 vancomycin resistant enterococcal isolates. J. Antimicrob. Chemother. 37:847-849.
10. Coque, T. M., K. V. Singh, and B. E. Murray. 1996. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci. J. Antimicrob. Chemother. 37:1011-1016.
11. Coque, T. M., K. V. Singh, and B. E. Murray. 1996. Assessment of the bactericidal activity of trovafloxacin (CP 99,129) against multiresistant strains of enterococci, abstr. E77, p. 95. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Edmond, M. B., J. F. Ober, D. L. Weinbaum, M. L. Pfaller, T. Hwang, M. D. Sanford, and R. P. Wenzel. 1995. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. 20:1126-1133.
13. Endtz, H. P., J. W. Mouton, J. G. den Hollander, N. van den Braak, and H. A. Verbrugh. 1997. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob. Agents Chemother. 41:1146-1149.
14. Firsov, A. A., D. Savarino, M. Ruble, D. Gilbert, B. Manzano, A. A. Medeiros, and S. H. Zinner. 1996. Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob. Agents Chemother. 40:734-738.
15. Herrera-Insua, I., K. Jacques-Palaz, B. E. Murray, and R. M. Rakita. 1996. Intracellular activity of trovafloxacin (CP-99,219) against vancomycin-susceptible (VSEF) and vancomycin-resistant (VREF) Enterococcus faecium, abstr. E78, p. 95. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Jenkins, S. G. 1996. In vitro synergy between trovafloxacin and ampicillin/sulbactam against bacterial pathogens, abstr. E82, p. 96. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Kinishi, T. 1993 Pharmacokinetic profile of antimicrobial agents. II-1. Penicillins, p. 43-64. In H.-P. Kuemmerle, T. Murakawa, and C. H. Nightingale (ed.), Pharmacokinetics of antimicrobial agents: principles, methods, application. Ecomed Verlag, Landsberg, Germany.
18. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36:385-394.
19. Wells, C. L., B. A. Juni, S. B. Cameron, K. R. Mason, D. L. Dunn, P. Ferrieri, and F. S. Rhame. 1995. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin. Infect. Dis. 21:45-50.